We seek to discover novel and alternative treatment approaches for primary, locally recurrent and secondary (metastatic) ocular melanoma.
Our current research in this field include:
Eye cancer results in the loss of vision or an eye. Medical outcomes are often poor and there are very limited treatment options.
Types of eye cancer include:
Secondary growths (also known as systemic metastases) are the main cause of early death in all types of ocular melanoma. These secondary tumours grow rapidly, are resistant to conventional chemotherapy and usually cause death within 12 months.
Our team continues to conduct research at the Save Sight Institute laboratories and collaborate with Kinghorn Cancer Centre, St Vincent's Hospital to discover better treatments for ocular melanoma.
We are now undertaking transitional studies in vitro to examine the use of HDAC inhibitors in combination with standard chemotherapy agents and other novel treatment approaches.
Our cell culture studies examine the potential for new topical intraocular and/or combination therapies. These studies have received the involvement of Master of Medicine (Ophthalmic Science) and optometry students.
Our current studies include:
Preliminary results have been presented and are being prepared for publication.